Amendment No. 1
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Amendment
No. 1
|
Between
|
Bayer
Schering Pharma AG
|
|
Xxxxxxxxxxxxx 000
|
|
|
00000
Xxxxxx, Xxxxxxx
|
|
|
(hereinafter
referred to as “Bayer“)
|
|
|
and
|
Micromet
AG
|
|
Xxxxxxxxxxxxxxxxx
0
|
|
|
00000
Xxxxxx, Xxxxxxx
|
|
|
(hereinafter
referred to as “Micromet”)
|
|
|
(each
hereafter referred to as a “Party” or collectively referred to as the
“Parties”)
|
WHEREAS:
Bayer and
Micromet entered into an Option, Collaboration and License Agreement relating to
BiTE antibodies on January 12, 2009 (hereinafter referred to as “the
Agreement”).
Whereby
the Parties wish to agree on certain clarifications and modifications to the
Agreement in connection with the exercise by Bayer of the option under the
Agreement.
Now,
THEREFORE the Parties hereby agree as follows in this Amendment No. 1 (the
“Amendment”):
|
1.
|
DEFINITIONS
|
Unless
otherwise defined herein, capitalized terms shall have the same meaning as set
forth in the Agreement.
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
|
2.
|
EXERCISE
OF THE OPTION; EFFECTIVENESS OF
AMENDMENT
|
Effective
as of the date hereof, Bayer has exercised the Option pursuant to that separate
letter delivered by Bayer and attached hereto. The Parties hereby
agree and acknowledge that notwithstanding anything else stated in Section 2.3
of the Agreement Bayer will be granted the rights in the Agreement and all of
the terms and conditions of the Agreement (as amended herein) will be binding on
the Parties as of the date of this Amendment, which shall be considered the
License Effective Date. Notwithstanding anything else stated in
Section 2.3 of the Agreement, the Option Exercise Fee shall be payable, subject
to receipt of a proper invoice, on January 8, 2010, irrespective of the date of
the License Effective Date.
|
3.
|
[***] DEVELOPMENT
PLAN
|
Notwithstanding
anything else stated in Section 4.1 or 4.3 of the Agreement, the Parties hereby
agree to an updated [***] Development Plan which is
attached to this Amendment and shall replace in its entirety the original Exhibit
B.
|
4.
|
EXHIBIT
C
|
Exhibit C shall be
replaced in its entirety by the updated version attached to this
Amendment.
|
5.
|
PAYMENTS
UNDER THIRD PARTY AGREEMENTS
|
|
5.1
|
The
second sentence of Section 8.4.1 shall be
amended to read as follows:
|
“[…]In
addition, Bayer will be responsible for (i) the payments that become due under
any future agreement Bayer enters into with a Third Party with regard to the
Product, except as set forth in Section 8.4.2; and
(ii) [***] ( [***] ) of any payments that become due under
any potential license to or acquisition of one or more Patents from a Third
Party listed on Attachment 4 (whether
entered into by Bayer or by Micromet), provided that with regard to royalty
payments, Bayer’s share of the payment obligations under this subsection (ii)
for such Third Party agreement shall be limited to a royalty rate
of [***] percent. Bayer and Micromet will
continuously consult with each other during the negotiation of and jointly
approve any license or acquisition agreement covered by subsection (ii) above,
such approval not to be unreasonably withheld; it being understood that, subject
to Section 4.8 with respect to any subsequent negotiation right of
Bayer, Micromet shall have the first right to obtain such license
under commercially reasonable terms, including but not limited to a reasonable
allocation of early and late payments in accordance with industry standards and
similar to the allocation of early and late payments from Bayer to Micromet
under this Agreement, as the Parties may determine.
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
|
5.2
|
The
second sentence of Section 8.4.2 shall be
amended to read as follows:
|
“[…] In
addition, Micromet will be responsible for (i) the payments that become due
under any license to or acquisition of Patents (whether entered into by Bayer or
by Micromet) from a Third Party (including a [***] ) to the extent
payments are payable for a license to or acquisition of Patents owned by a Third
Party that would [***] by [***] of
an [***] in a [***] listed on [***] , except excluding any
such invention relating to the [***] and
(ii) [***] ( [***] ) of any payments that become due under
any potential license to or acquisition of one or more Patents from a Third
Party listed on Attachment 4 (whether
entered into by Bayer or by Micromet), provided that with regard to royalty
payments, Micromet’s share of the payment obligations under this subsection (ii)
for such Third Party agreement shall be limited to a royalty rate
of [***] percent.”
|
5.3
|
The
following sentence shall be added to Section 8.4.2 and read as
follows:
|
“Upon
execution by Micromet of an agreement relating to a license to or acquisition of
one or more Patents listed on Attachment 4 or any
other agreements with Third Parties for which Micromet is financially
responsible in accordance with the cost allocation described in Section 8.4.2,
such Patents Controlled by Micromet shall become part of the Sublicensed
Technology and be included in the licenses granted to Bayer under the Agreement,
subject to the terms and conditions of the agreement with the Third Party and
without additional payment obligations of Bayer other than those set out in
Section 8.4.1 and subject to those payment obligations described in the last
sentence of the first paragraph of this Section 8.4.2.
5.4 The
Parties agree that a license granted to Bayer under one or more Patents listed
in Attachment 4
shall not extend the royalty term for royalties payable according to Section
8.3.1. Section 8.3.2 (b) shall therefore be amended to read as
follows:
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
“(b) Royalties
due under the preceding Section 8.3.1 will commence upon First Commercial Sale
of a Product in a particular country in the Territory and will expire on a
country-by-country and Product-by-Product basis upon the later of: (i) the
expiration of the last-to-expire Patent within the Licensed Technology
containing a Valid Claim claiming or covering the use or sale of such Product in
such country, or (ii) [***] ( [***] ) [***] from
the First Commercial Sale of such Product in such country; provided, however,
that once the use or sale of a Product in a particular country is only claimed
or covered by a Valid Claim within the Patents listed in Attachment 4, and
the [***] period pursuant to the preceding subsection (ii)
has expired, Bayer shall no longer pay to Micromet royalties according to
Section 8.3.1 for such country, but only such royalties that Micromet has to pay
to a Third Party for the use of those Patents by virtue of Bayer’s
Commercialization of the Product.
|
6.
|
EFFECTS
OF TERMINATION
|
|
6.1
|
Section
13.1.1 (i) shall be amended to read as
follows:
|
“(i) [***]
to [***] a [***] with the [***]
to [***] and [***] the [***]
of [***] under any [***] related to any of the items described in
Section [***] and under any [***] or [***]
by [***] that would be [***] or
is [***] by the [***] or [***] of
the [***] to [***] for [***]
and [***] the [***] in the [***] provided that
where [***] has to [***] to a [***] for
the [***] of any [***] or [***] to
be [***] to [***] under this Section 13.1.1(i), such [***]
shall only be [***] if [***] to [***]
to [***] any [***] which [***] to
the [***] to the extent [***] to the [***]
or [***] of the [***] by or on behalf of [***]
”
|
6.2
|
The
first sentence of Section 13.1.2 shall be deleted and replaced by the
following:
|
“If the
Agreement is terminated by Micromet under [***] or by
Bayer under [***] in its entirety or with respect to any
Terminated Territory after the [***] of the [***] in
the [***] , in consideration of the Program Transfer, Micromet will
make to Bayer payments according to the following schedule until such time as
Bayer has received an amount equivalent to [***] times
the [***] and [***] (including, but not limited to [***]
) [***] by it or paid to [***] pursuant to this
Agreement for the Product in respect of such Terminated Territory, but, for
clarity, excluding any milestone or royalty payments paid to Micromet (“the
Compensation”): […]”
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
|
7.
|
PRESS
RELEASE UPON OPTION EXERCISE
|
On the
License Effective Date or first Business Day thereafter, each Party may issue
the press release regarding the exercise of the Option in the form attached in
Attachment
5.
|
8.
|
CONFIRMATION
OF TERMS
|
Except as
expressly amended by the terms hereof, all provisions of the Agreement shall
remain in full force and effect.
In
witness whereof the Parties have executed this Amendment No. 1 as of the dates
set forth below.
|
Bayer
Schering Pharma AG
|
Micromet
AG
|
|||
|
Date: November
25, 2009
|
Date:
November 25, 2009
|
|||
|
By:
|
/s/ Andreas Fibig
|
By:
|
/s/ Xxxx Xxxxxxxx
|
|
|
Name: Andreas
Fibig
|
Name:
Xxxx Xxxxxxxx
|
|||
|
Function:
Chairman of the Board
|
Function:
SVP Business Development
|
|||
|
of
Management
|
||||
|
By:
|
/s/ Xxxxxxx Xxxxx
|
By:
|
/s/ Xxxxxxx Xxxxxxxx
|
|
|
Name: Prof.
Xx. Xxxxxxx Xxxxx
|
Name:
Xxxxxxx Xxxxxxxx
|
|||
|
Function:
Member of the Board of
|
Function:
SVP R&D, CSO
|
|||
|
Management
|
||||
Attachments:
1. Updated
Exhibit B
2. Updated
Exhibit C
3. Option
Exercise Letter
4. Patent
List
5. Micromet
and Bayer Press Release
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
ATTACHMENT
1
Updated
Exhibit B
[Attachment
follows]
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
[***]
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
ATTACHMENT
2
Exhibit
C
Micromet
Technology Patents
[***]
|
Application
Number
|
Application
Filing Date
|
Country
|
Title of Application
|
Status
|
Patent Number
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
Application
Number
|
Application
Filing Date
|
Country
|
Title of Application
|
Status
|
Patent Number
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
*** Certain confidential
information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
|
Application
Number
|
Application
Filing Date
|
Country
|
Title of Application
|
Status
|
Patent Number
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
Application
Number
|
Application
Filing Date
|
Country
|
Title of Application
|
Status
|
Patent Number
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
Application
Number
|
Application
Filing Date
|
Country
|
Title of Application
|
Status
|
Patent Number
|
|||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||||||
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
ATTACHMENT
3
Option
Exercise Letter
[Attachment
follows]
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
 |
 |
By
fax and courier
Micromet
AG
Attn.:
Head of Business Development
Xxxxxxxxxxxxx.
0
00000
Xxxxxxx
Fax no.:
089 / 000 000 000
|
Option,
Collaboration and License Agreement dated January 12,
2009:
Option
Exercise Notice
Dear
Sir,
In
accordance with Section 2.3 of the above mentioned Option, Collaboration
and License Agreement (“the Agreement”) we hereby provide notice to
Micromet of Bayer Schering Pharma’s desire to exercise the Option as
defined in Section 2.1 of the Agreement. This letter shall constitute the
Option Exercise Notice pursuant to Section 2.3 of the
Agreement.
Yours
sincerely,
Bayer
Schering Pharma AG
Andreas
Fibig Prof.
Xx. Xxxxxxx Xxxxx
Chairman
of the Board of Management
Member of the Board of Management
cc:
Attn.:
General Counsel
0000
Xxxxxxxxx Xxxxxxxxx, Xxxxx 000
Xxxxxxxx,
XX 00000, XXX
Fax
no.: x0-000-000-0000
|
November
25, 2009
Bayer
Schering Pharma AG
Sd/9b2411_1
Postal
address:
00000
Xxxxxx, Xxxxxxx
Visitor’s
address:
Xxxxxxxxxxxx
000
00000
Xxxxxx, Xxxxxxx
Tel.
x00 00 000 0000
Fax
x00 00 000
@
xxx.xxxxxxxxxxxxxxxxxxx.xx
Board
of Management:
Andreas
Fibig,
Chairman
of the Board
Xxxxxxx
Xxxxx
Xxxxxx
Xxxxxxx
Xxxxx
Xxxxx
Xxxxx
Xxxxxxx
Chairman
of the
Supervisory
Board:
Xxxxxxx
Xxxx
Registered
Office:
Berlin
Local
Court
Charlottenburg
HRB
283
B
|
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
ATTACHMENT
4
Patent
List
|
Publication Number
|
Filing Date
|
Country
|
Title of Application
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
|||
|
[***]
|
[***]
|
[***]
|
[***]
|
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
ATTACHMENT
5
Micromet
and Bayer Press Release
[Attachment
follows]
***
Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
PRESS
RELEASE
Bayer
Schering Exercises Option to Develop Solid Tumor BiTE Antibody with
Micromet
BETHESDA, MD – December 1, 2009
— Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company developing
novel, proprietary antibodies for the treatment of cancer, inflammation and
autoimmune diseases today announced that Bayer Schering Pharma AG has exercised
its option under the option, collaboration and license agreement entered into on
January 12, 2009 to develop a new BiTE antibody for the treatment of solid
tumors.
Under the
terms of the agreement, Bayer Schering Pharma had an option until January 5,
2010 to license a specific BiTE antibody targeting an undisclosed target. The
option exercise triggers a formal collaboration between Micromet and Bayer
Schering Pharma on the development of the BiTE antibody. Micromet will be
primarily responsible for the preclinical development of the BiTE antibody, and
will collaborate with Bayer through the completion of phase 1 clinical trials,
at which point Bayer Schering Pharma will assume full control of the further
development and commercialization of the BiTE antibody. Micromet will receive an
option exercise fee of Euro 5 million (approx. $7.5 million), and is eligible
for further milestone payments of up to Euro 285 million (approx. $426 million)
in total and up to double digit royalties on net sales of the BiTE antibody. In
addition, Micromet will be reimbursed for its R&D expenses.
“BiTE
antibodies represent a promising approach to cancer therapy,” said Xx. Xxxx
Xxxxxxxxxxx, Head Therapeutic Research Oncology of Bayer Schering Pharma AG. “We
are pleased with the progress of the program since the signing of the agreement
in January of this year. We are looking forward to developing a new treatment
for patients with solid tumors and to further advance novel therapeutic options
in our oncology portfolio.”
Xxxx
Xxxxxxxx, Micromet’s Senior Vice President for Business Development added: “Our
research and preclinical development teams have done an excellent job in
advancing the program since January of this year. Bayer Schering Pharma’s early
option exercise is a recognition of Micromet’s development capabilities and
confirms the promise of our BiTE antibody platform.”
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
Page 1 of
3
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
About
BiTE Antibodies
BiTE®
antibodies are designed to direct the body's cytotoxic, or cell-destroying, T
cells against tumor cells, and represent a new therapeutic approach to cancer
therapy. Typically, antibodies cannot engage T cells because T cells lack the
appropriate receptors for binding antibodies. BiTE antibodies have been shown to
bind T cells to tumor cells, ultimately inducing a self-destruction process in
the tumor cells referred to as apoptosis, or programmed cell death. In the
presence of BiTE antibodies, T cells have been demonstrated to serially
eliminate tumor cells, which explains the activity of BiTE antibodies at very
low concentrations. Through the killing process, T cells start to proliferate,
which leads to an increased number of T cells at the site of
attack.
About
Micromet, Inc.
Micromet,
Inc. is a biopharmaceutical company developing novel, proprietary antibodies for
the treatment of cancer, inflammation and autoimmune diseases. Its product
development pipeline includes novel antibodies generated with its proprietary
BiTE® antibody platform, as well as conventional monoclonal antibodies. Two of
Micromet’s BiTE antibodies and three of its conventional antibodies are
currently in clinical trials. Micromet's preclinical product pipeline includes
several novel BiTE antibodies generated with its proprietary BiTE antibody
platform technology. Micromet’s collaboration partners include sanofi-aventis,
Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.
Forward-Looking
Statements
This release contains certain
forward-looking statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. These
forward-looking statements include statements regarding the operation of the
global collaboration with Bayer Schering Pharma, the efficacy, safety and
intended utilization of our product candidates, including the BiTE antibody that
is the subject of the agreement with Bayer Schering Pharma, the mode of action
of BiTE antibodies, the conduct, timing and results of future clinical trials,
expectations of the future expansion of our product pipeline and collaborations,
and the future payment of milestone and royalty payments by Bayer Schering
Pharma. You are urged to consider statements that include the words "ongoing,"
"may," "will," "believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to be uncertain
and forward-looking. Factors that may cause actual results to differ materially
from any future results expressed or implied by any forward-looking statements
include the risk that product candidates that appeared promising in early
research, preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk
that encouraging results from early research, preclinical studies or clinical
trials may not be confirmed upon further analysis of the detailed results of
such research, preclinical study or clinical trial, the risk that additional
information relating to the safety, efficacy or tolerability of our product
candidates may be discovered upon further analysis of preclinical or clinical
trial data, the risk that we or our collaborators will not obtain approval to
market our product candidates, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated with reliance
on collaborators and licensees, including Bayer Schering Pharma, sanofi-aventis,
MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of
further development and commercialization activities relating to our product
candidates. These factors and others are more fully discussed in Micromet's
Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2009,
filed with the SEC on November 6, 2009, as well as other filings by the company
with the SEC.
# #
#
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
Page 2 of
3
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
|
Contact
Information
|
||
|
US
Media:
|
European
Media:
|
|
|
Xxxxx
Xxxxx
|
Xxxxxx
Xxxx
|
|
|
(000)-000-0000
|
x00
(00) 0000 0000
|
|
|
xxxxxxxx@xxxxxxxx-xx.xxx
|
xxxxxx@xxxxxxxx.xxx
|
|
|
US
Investors:
|
European
Investors:
|
|
|
Xxxxx
Xxxxxx
|
Xxxx-Xxxxxx
Xxxx
|
|
|
(000)
000-0000
|
x00
(00) 0000 0000
|
|
|
xxxxx@xxxxxxxx.xxx
|
xxxx@xxxxxxxx.xxx
|
|
*** Certain confidential
information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities Exchange Act of 1934, as amended.
Page 3 of
3
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
 |
|
|
Final Draft November 22, 2009
|
|
|
News Release
|
Bayer HealthCare XX
Xxxxxxxxx Xxxxxxxxxxxxxx
00000 Xxxxxxxxxx
Xxxxxxx
Phone x00 000 00 0
xxx.xxxx.xxxxx.xxx
|
Development of new BiTE
antibody for treatment of solid tumors:
Bayer
Schering Pharma to collaborate with Micromet on novel approach to cancer
therapy
Berlin, December 1st, 2009 –
Bayer Schering Pharma AG, Germany, will develop a new BiTE antibody for the
treatment of solid tumors in collaboration with the biopharmaceutical company
Micromet, Inc. In January 2009, both companies had entered into an option,
license and collaboration agreement. By exercising the option today, Bayer
Schering Pharma has triggered a joint collaboration on the development of the
BiTE antibody against an undisclosed solid tumor target through the completion
of Phase I clinical trials, at which point Bayer will assume full control of the
further development and commercialization of the antibody. BiTE antibodies are
designed to direct the body's cell-destroying T cells against tumor cells, and
represent a new therapeutic approach to cancer therapy.
Bayer
Schering Pharma will pay Micromet an option exercise fee of 5 million Euro in
January 2010. According to the agreement, Micromet will be eligible for
milestone payments of up to 285 million Euro in total and up to double-digit
royalties based on tiered net sales of the product. In addition it is planned to
reimburse Micromet for its R&D expenses.
”BiTE
antibodies represent a promising approach to cancer therapy,” said Xx. Xxxx
Xxxxxxxxxxx, Head Therapeutic Research Oncology of Bayer Schering Pharma AG. “We
are pleased with the progress of the program since the signing of the agreement
in January of this year. We are looking forward to developing a new treatment
for patients with solid tumors and to further advance novel therapeutic options
in our oncology portfolio.”
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
- 1/3
-
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Xxxx
Xxxxxxxx, Micromet’s Senior Vice President for Business Development added: “Our
research and preclinical development teams have done an excellent job in
advancing the program since January of this year. Bayer Schering Pharma’s early
option exercise is a recognition of Micromet’s development capabilities and
confirms the promise of our BiTE antibody platform.”
The Bayer
Group is a global enterprise with core competencies in the fields of health
care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Xxxxx
XX, is one of the world’s leading, innovative companies in the healthcare and
medical products industry and is based in Leverkusen, Germany. The company
combines the global activities of the Animal Health, Bayer Schering Pharma,
Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover
and manufacture products that will improve human and animal health worldwide.
Find more information at xxx.xxxxxxxxxxxxxxx.xxx.
Bayer
Schering Pharma is a worldwide leading specialty pharmaceutical company. Its
research and business activities are focused on the following areas: Diagnostic
Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With
innovative products, Bayer Schering Pharma aims for leading positions in
specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to
make a contribution to medical progress and strives to improve the quality of
life. Find more information at xxx.xxxxxxxxxxxxxxxxxxx.xx.
Contact:
Xxxxxx
Rennmann, Phone: +49 30 - 000 00000
E-mail:
xxxxxx.rennmann@ xxxxxxxxxxxxxxx.xxx
DR (2009-0633E)
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
- 2/3
-
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Forward-Looking
Statements
This
release may contain forward-looking statements based on current assumptions and
forecasts made by Bayer Group or subgroup management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer’s public reports which are available on the Bayer
website at xxx.xxxxx.xxx. The
company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
- 3/3
-
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
|
|
|
|
Endgültiger
Entwurf vom 22.11.2009
|
|
|
Presse-Information
|
Bayer HealthCare XX
Xxxxxxxxxxxxxxxxxxxxxxxxx
00000 Xxxxxxxxxx
Xxxxxxxxxxx
Tel.:
0000 00-0
xxx.xxxxxx.xxxxx.xx
|
Entwicklung eines
BiTE-Antikörpers zur Behandlung solider Tumore:
Bayer
Schering Pharma arbeitet zusammen mit Micromet an neuem Ansatz in der
Krebstherapie
Berlin, 1. Dezember 2009 –
Bayer Schering Pharma arbeitet zusammen mit dem biopharmazeutischen
Unternehmen Micromet an der Entwicklung eines neuen, spezifischen
BiTE-Antikörpers zur Behandlung solider Tumore. Im Januar 2009 xxxxxx beide
Unternehmen eine Exklusivoption für eine Kooperations- und Lizenzvereinbarung
unterschrieben. Diese Option hat Bayer Schering Pharma heute ausgeübt und die
Zusammenarbeit begonnen.
Der
BiTE-Antikörper gegen solide Tumore soll bis zum erfolgreichen Abschluss der
Phase I der klinischen Studien gemeinsam entwickelt werden. Anschließend wird
Bayer Schering Pharma die weitere Entwicklung und Vermarktung vollständig
übernehmen. BiTE-Antikörper sollen die körpereigenen “Killer-T-Zellen“ gegen die
Tumorzellen lenken. Dies ist ein neuer Ansatz in der Krebstherapie.
Laut
Vereinbarung wird Bayer Schering Pharma im Januar 2010 für die Ausübung der
Option eine Gebühr von 5 Millionen Euro an Micromet zahlen. Insgesamt soll
Micromet meilensteinabhängige Zahlungen von bis zu 285 Millionen Euro erhalten.
Hinzu kommen gestaffelte Lizenzgebühren je nach den Umsätzen des Präparats bis
in den zweistelligen Prozent-Bereich. Außerdem ist vorgesehen, dass Micromet
Ausgleichzahlungen für seinen Entwicklungsaufwand erhält.
”BiTE-Antikörper
sind ein vielversprechender Ansatz in der Krebstherapie,“ kommentierte Xx. Xxxx
Xxxxxxxxxxx, Xxxxxx des therapeutischen Forschungsgebiets Onkologie bei Bayer
Schering Pharma. „Wir haben den Fortschritt des Programms seit unserer
Vereinbarung im Januar 2009 mit großem Interesse verfolgt und freuen uns jetzt
auf die Entwicklung einer neuen Behandlungsmöglichkeit für
Patienten mit soliden Tumoren. Wir bauen so unser Onkologie-Portfolio mit
neuartigen Therapieoptionen aus.“
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
- 1/3
-
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Xxxx
Xxxxxxxx, Senior Vice President für Business Development bei Micromet, ergänzte:
„Unsere Teams in Forschung und präklinischer Entwicklung haben seit Januar sehr
erfolgreich daran gearbeitet, das Programm voranzubringen. Dass Bayer Schering
Pharma seine Option schon jetzt ausübt, ist für uns auch eine Anerkennung
unserer Fähigkeiten in der Arzneimittelentwicklung. Außerdem bestätigt es die
guten Aussichten unserer BiTE-Antikörper.“
Über
Bayer Schering Pharma
Die Xxxxx
XX ist ein weltweit tätiges, forschungsbasiertes und wachstumsorientiertes
Unternehmen
mit Kernkompetenzen auf den Gebieten Gesundheit, Ernährung und hochwertige
Materialien. Bayer HealthCare ist eine Tochtergesellschaft der Xxxxx XX und
gehört zu den weltweit führenden innovativen Unternehmen in der
Gesundheits-versorgung mit Arzneimitteln und medizinischen Produkten. Das
Unternehmen bündelt die Aktivitäten der Divisionen Animal Health, Bayer Schering
Pharma, Consumer Care sowie Medical Care. Ziel xxx Xxxxx HealthCare ist es,
Produkte zu erforschen, zu entwickeln, zu produzieren und zu vertreiben, um die
Gesundheit xxx Xxxxxx und Tier weltweit zu verbessern. Mehr Informationen finden
Sie unter xxx.xxxxxxxxxxxxxxx.xxx.
Bayer
Schering Pharma ist ein weltweit führendes Spezialpharma-Unternehmen, dessen
Forschung und Geschäftsaktivitäten sich auf vier Bereiche konzentrieren:
Diagnostische Bildgebung, General Medicine, Specialty Medicine und Women’s
Healthcare. Bayer Schering Pharma setzt auf Innovationen und will mit neuartigen
Produkten in speziellen Märkten weltweit führend sein. So leistet Bayer Schering
Pharma einen Beitrag zum medizinischen Fortschritt und will die Lebensqualität
der Menschen verbessern. Mehr Informationen finden Sie unter
xxx.xxxxxxxxxxxxxxxxxxx.xx.
Ansprechpartnerin:
Xxxxxx
Rennmann, Tel.: 0 00-00 00 00 00
E-Mail:
xxxxxx.rennmann@ xxxxxxxxxxxxxxx.xxx
DR (2009-0633)
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
- 2/3
-
***Text
Omitted and Filed Separately
Confidential
Treatment Requested
Under
17 C.F.R. §§ 200.80(b)(4), and 240.24b-2
Zukunftsgerichtete
Aussagen
Diese
Presseinformation kann bestimmte in die Zukunft gerichtete Aussagen enthalten,
die auf den gegenwärtigen Annahmen und Prognosen der Unternehmensleitung des
Bayer-Konzerns bzw. seiner Teilkonzerne beruhen. Verschiedene bekannte wie auch
unbekannte Risiken, Ungewissheiten und andere Faktoren können dazu führen, dass
die tatsächlichen Ergebnisse, die Finanzlage, die Entwicklung oder die
Performance der Gesellschaft wesentlich von den hier gegebenen Einschätzungen
abweichen. Diese Faktoren schließen diejenigen ein, die Bayer in
veröffentlichten Berichten beschrieben hat. Diese Berichte stehen auf der
Bayer-Webseite xxx.xxxxx.xx zur
Verfügung. Die Gesellschaft übernimmt keinerlei Verpflichtung, solche
zukunftsgerichteten Aussagen fortzuschreiben und an zukünftige Ereignisse oder
Entwicklungen anzupassen.
*** Certain confidential information contained in this document,
marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended.
- 3/3
-
